About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

MagnetisMM-32 is an open-label, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of ELREXFIO monotherapy versus investigator’s choice among three standard-of-care regimens ...

Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced ...

Pfizer reported third-quarter 2026 results on November 3 that exceeded the company’s expectations. The company’s commercial performance globally and continued financial discipline led to it raising ...

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

The seasons are changing and the weather is getting cooler, but our social media round-up is hot off the presses. As usual, we are sharing the latest and greatest updates from the last month. In ...

Pfizer is a well-established name that’s proud to shape Ireland’s thriving pharmaceuticals industry. We are home to around 3,700 people in six sites in Ireland, delivering skills across manufacturing, ...

We can't wait for you to join us! To help you prepare, we’ve created an onboarding experience that will get you ready for day one, give you an opportunity to learn more about the business, and start ...

This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails ...

It started with a breakthrough. The year was 1849, and people everywhere were getting sick to their stomachs. In the days before widespread refrigeration, a simple meal of meat and potatoes could ...